Deferasirox + Deferasirox
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Iron Overload
Conditions
Liver Iron Overload
Trial Timeline
Feb 1, 2003 → Jan 1, 2008
NCT ID
NCT01033747About Deferasirox + Deferasirox
Deferasirox + Deferasirox is a phase 2/3 stage product being developed by Novartis for Liver Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01033747. Target conditions include Liver Iron Overload.
What happened to similar drugs?
20 of 20 similar drugs in Liver Iron Overload were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01892644 | Phase 2 | Withdrawn |
| NCT01033747 | Phase 2/3 | Completed |
Competing Products
20 competing products in Liver Iron Overload